Cargando…
Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827158/ https://www.ncbi.nlm.nih.gov/pubmed/36073517 http://dx.doi.org/10.3324/haematol.2022.281221 |
| _version_ | 1784867013886214144 |
|---|---|
| author | Stalder, Grégoire Suffiotti, Madeleine Segot, Amandine Noto, Alessandra Pantaleo, Giuseppe Spertini, Olivier Obeid, Michel |
| author_facet | Stalder, Grégoire Suffiotti, Madeleine Segot, Amandine Noto, Alessandra Pantaleo, Giuseppe Spertini, Olivier Obeid, Michel |
| author_sort | Stalder, Grégoire |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9827158 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98271582023-01-20 Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial Stalder, Grégoire Suffiotti, Madeleine Segot, Amandine Noto, Alessandra Pantaleo, Giuseppe Spertini, Olivier Obeid, Michel Haematologica Letter to the Editor Fondazione Ferrata Storti 2022-09-08 /pmc/articles/PMC9827158/ /pubmed/36073517 http://dx.doi.org/10.3324/haematol.2022.281221 Text en Copyright© 2023 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letter to the Editor Stalder, Grégoire Suffiotti, Madeleine Segot, Amandine Noto, Alessandra Pantaleo, Giuseppe Spertini, Olivier Obeid, Michel Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial |
| title | Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial |
| title_full | Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial |
| title_fullStr | Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial |
| title_full_unstemmed | Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial |
| title_short | Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial |
| title_sort | response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adred) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827158/ https://www.ncbi.nlm.nih.gov/pubmed/36073517 http://dx.doi.org/10.3324/haematol.2022.281221 |
| work_keys_str_mv | AT staldergregoire responseadjustedregimencombiningruxolitinibetoposideanddexamethasoneadredinadultpatientswithacutemyeloidleukemiaassociatedhemophagocyticlymphohistiocytosisasinglecenterpilottrial AT suffiottimadeleine responseadjustedregimencombiningruxolitinibetoposideanddexamethasoneadredinadultpatientswithacutemyeloidleukemiaassociatedhemophagocyticlymphohistiocytosisasinglecenterpilottrial AT segotamandine responseadjustedregimencombiningruxolitinibetoposideanddexamethasoneadredinadultpatientswithacutemyeloidleukemiaassociatedhemophagocyticlymphohistiocytosisasinglecenterpilottrial AT notoalessandra responseadjustedregimencombiningruxolitinibetoposideanddexamethasoneadredinadultpatientswithacutemyeloidleukemiaassociatedhemophagocyticlymphohistiocytosisasinglecenterpilottrial AT pantaleogiuseppe responseadjustedregimencombiningruxolitinibetoposideanddexamethasoneadredinadultpatientswithacutemyeloidleukemiaassociatedhemophagocyticlymphohistiocytosisasinglecenterpilottrial AT spertiniolivier responseadjustedregimencombiningruxolitinibetoposideanddexamethasoneadredinadultpatientswithacutemyeloidleukemiaassociatedhemophagocyticlymphohistiocytosisasinglecenterpilottrial AT obeidmichel responseadjustedregimencombiningruxolitinibetoposideanddexamethasoneadredinadultpatientswithacutemyeloidleukemiaassociatedhemophagocyticlymphohistiocytosisasinglecenterpilottrial |